INTERLEUKIN GENETICS, INC.Interleukin Genetics Inc • November 18th, 2015 • In vitro & in vivo diagnostic substances • Delaware
As of April 6, 2015 (the “Grant Date”), Interleukin Genetics, Inc. (the “Company”), a Delaware corporation, grants to Mark Carbeau (the “Participant”) the right and option (the “Option”) to purchase up to 11,622,279 shares of the common stock, $.001 par value per share, of the Company (the “Shares”) at a purchase price of $0.1525 per share (the “Purchase Price”) on the terms and conditions and subject to all the limitations set forth in this Agreement. For the purpose of this Agreement, the initial vesting date shall be April 6, 2016 (“Initial Vesting Date”).
